Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2014 (2014), Article ID 194185, 6 pages
http://dx.doi.org/10.1155/2014/194185
Review Article

Development of the Rat Model of Lapatinib-Induced Diarrhoea

School of Medical Sciences, University of Adelaide, Frome Road, Adelaide, SA 5005, Australia

Received 25 December 2013; Revised 22 June 2014; Accepted 24 June 2014; Published 7 July 2014

Academic Editor: Marcella Mottolese

Copyright © 2014 Joanne M. Bowen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Alimonti, A. Gelibter, I. Pavese et al., “New approaches to prevent intestinal toxicity of irinotecan-based regimens,” Cancer Treatment Reviews, vol. 30, no. 6, pp. 555–562, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Gibson and D. M. K. Keefe, “Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies,” Supportive Care in Cancer, vol. 14, no. 9, pp. 890–900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Sharma, P. Tobin, and S. J. Clarke, “Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea,” The Lancet Oncology, vol. 6, no. 2, pp. 93–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Kitagawa, K. Yokota, M. Gouda et al., “Activity-based kinase profiling of approved tyrosine kinase inhibitors,” Genes to Cells, vol. 18, no. 2, pp. 110–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. K. Keefe and R. J. Gibson, “Mucosal injury from targeted anti-cancer therapy,” Supportive Care in Cancer, vol. 15, no. 5, pp. 483–490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Keefe and L. Anthony, “Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care,” Current Opinion in Supportive and Palliative Care, vol. 2, no. 1, pp. 19–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Thomas, F. V. Fossella, D. Liu et al., “Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program,” Clinical Lung Cancer, vol. 7, no. 5, pp. 326–331, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Hirsh, “Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer,” Current Oncology, vol. 18, no. 3, pp. 126–138, 2011. View at Google Scholar · View at Scopus
  9. P. Chen, L. Wang, B. Liu, H. Zhang, H. Liu, and Z. Zou, “EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis,” European Journal of Clinical Pharmacology, vol. 67, no. 3, pp. 235–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. E. W. Cohen, A. B. Halpern, K. Kasza, M. Kocherginsky, R. Williams, and E. E. Vokes, “Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck,” Oral Oncology, vol. 45, no. 10, pp. e155–e160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Petrelli, K. Borgonovo, M. Cabiddu, V. Lonati, and S. Barni, “Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials,” Lung Cancer, vol. 78, no. 1, pp. 8–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Crown, H. A. Burris III, F. Boyle et al., “Pooled analysis of diarrhea events in patients with cancer treated with lapatinib,” Breast Cancer Research and Treatment, vol. 112, no. 2, pp. 317–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. G. Chau and R. I. Haddad, “Vandetanib for the treatment of medullary thyroid cancer,” Clinical Cancer Research, vol. 19, no. 3, pp. 524–529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Morabito, M. C. Piccirillo, F. Falasconi et al., “Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions,” The Oncologist, vol. 14, no. 4, pp. 378–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Loriot, G. Perlemuter, D. Malka, F. Penault-Llorca, V. Boige, and E. Deutsch, “Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy,” Nature Clinical Practice. Oncology, vol. 5, no. 5, pp. 268–278, 2008. View at Publisher · View at Google Scholar
  16. H. A. Burris III, H. I. Hurwitz, E. C. Dees et al., “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5305–5313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Abbas, B. A. Hug, C. Leister, and D. Sonnichsen, “A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor,” Cancer Chemotherapy and Pharmacology, vol. 70, no. 1, pp. 191–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. M. Rudin, W. Liu, A. Desai et al., “Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1119–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Berlanga-Acosta, R. J. Playford, N. Mandir, and R. A. Goodlad, “Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats,” Gut, vol. 48, no. 6, pp. 803–807, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Harandi, A. S. Zaidi, A. M. Stocker, and D. A. Laber, “Clinical efficacy and toxicity of anti-EGFR therapy in common cancers,” Journal of Oncology, vol. 2009, Article ID 567486, 14 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. F. McCole and K. E. Barrett, “Decoding epithelial signals: Critical role for the epidermal growth factor receptor in controlling intestinal transport function,” Acta Physiologica, vol. 195, no. 1, pp. 149–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Medina and S. Goodin, “Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases,” Clinical Therapeutics, vol. 30, no. 8, pp. 1426–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. V. Keisner and S. R. Shah, “Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma,” Drugs, vol. 71, no. 4, pp. 443–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. P. van Erp, H. Gelderblom, and H. J. Guchelaar, “Clinical pharmacokinetics of tyrosine kinase inhibitors,” Cancer Treatment Reviews, vol. 35, no. 8, pp. 692–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Boerma, J. Wang, A. F. Burnett, A. D. Santin, J. J. Roman, and M. Hauer-Jensen, “Local administration of interleukin-11 ameliorates intestinal radiation injury in rats,” Cancer Research, vol. 67, no. 19, pp. 9501–9506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Bowen, A. M. Stringer, R. J. Gibson, A. S. Yeoh, S. Hannam, and D. M. Keefe, “VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss,” Cancer Biology & Therapy, vol. 6, no. 9, pp. 1449–1454, 2007. View at Google Scholar
  27. B. Watkins, K. Pouliot, E. Fey, C. Tuthill, and S. Sonis, “Attenuation of radiation-and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07),” Oral Diseases, vol. 16, no. 7, pp. 655–660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Bowen, B. J. Mayo, E. Plews et al., “Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea,” Cancer Biology and Therapy, vol. 13, no. 13, pp. 1269–1275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. D. W. Rusnak, K. Lackey, K. Affleck et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 85–94, 2001. View at Google Scholar · View at Scopus
  30. E. S. Henson and S. B. Gibson, “Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy,” Cellular Signalling, vol. 18, no. 12, pp. 2089–2097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Ryan, A. Ibrahim, M. H. Cohen et al., “FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2,” The Oncologist, vol. 13, no. 10, pp. 1114–1119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. H. A. Burris III, “Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib,” Oncologist, vol. 9, no. 3, pp. 10–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Baselga, I. Bradbury, H. Eidtmann et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial,” The Lancet, vol. 379, no. 9816, pp. 633–640, 2012. View at Google Scholar
  34. H. A. Azim Jr., D. Agbor-Tarh, I. Bradbury et al., “Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial,” Journal of Clinical Oncology, vol. 31, no. 36, pp. 4504–4511, 2013. View at Publisher · View at Google Scholar
  35. H. A. Burris III, C. W. Taylor, S. F. Jones et al., “A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies,” Clinical Cancer Research, vol. 15, no. 21, pp. 6702–6708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. M. Koch, N. J. Reddy, R. B. Cohen et al., “Effects of food on the relative bioavailability of lapatinib in cancer patients,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1191–1196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen, “The intestinotrophic peptide, GLP-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib,” Clinical Cancer Research, vol. 13, no. 17, pp. 5170–5175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Yusta, D. Holland, J. A. Koehler et al., “ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut,” Gastroenterology, vol. 137, no. 3, pp. 986–996, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. R. Rasmussen, N. Viby, K. J. Hare et al., “The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin,” Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2785–2796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. E. P. Mitchell, “Gastrointestinal toxicity of chemotherapeutic agents,” Seminars in Oncology, vol. 33, no. 1, pp. 106–120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Li, M. O. Karlsson, J. Brahmer et al., “CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors,” Journal of the National Cancer Institute, vol. 98, no. 23, pp. 1714–1723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-F. Lu, S. M. Eppler, J. Wolf et al., “Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer,” Clinical Pharmacology and Therapeutics, vol. 80, no. 2, pp. 136–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Gibson, J. M. Bowen, M. R. B. Inglis, A. G. Cummins, and D. M. K. Keefe, “Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer,” Journal of Gastroenterology and Hepatology, vol. 18, no. 9, pp. 1095–1100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. R. J. Gibson, J. M. Bowen, and D. M. K. Keefe, “Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats,” International Journal of Cancer, vol. 116, no. 3, pp. 464–470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. R. M. Logan, A. M. Stringer, J. M. Bowen, R. J. Gibson, S. T. Sonis, and D. M. K. Keefe, “Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?” Cancer Chemotherapy and Pharmacology, vol. 63, no. 2, pp. 239–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Bateman, J. Bowen, A. Stringer et al., “Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model,” Nutrients, vol. 5, pp. 3948–3936, 2013. View at Google Scholar
  47. R. B. Cohen, “Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)—and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC),” Cancer Treatment Reviews, vol. 40, pp. 567–577, 2014. View at Google Scholar